Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model.

Rizvi SZH, Shah FA, Khan N, Muhammad I, Ali KH, Ansari MM, Din FU, Qureshi OS, Kim KW, Choe YH, Kim JK, Zeb A.

Int J Pharm. 2019 Apr 5;560:136-143. doi: 10.1016/j.ijpharm.2019.02.002. Epub 2019 Feb 10.

PMID:
30753932
2.

Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells.

Hou TZ, Qureshi OS, Sansom DM.

Methods Mol Biol. 2019;1899:87-101. doi: 10.1007/978-1-4939-8938-6_7.

PMID:
30649767
3.

Folate-Functionalized Thiomeric Nanoparticles for Enhanced Docetaxel Cytotoxicity and Improved Oral Bioavailability.

Sajjad M, Khan MI, Naveed S, Ijaz S, Qureshi OS, Raza SA, Shahnaz G, Sohail MF.

AAPS PharmSciTech. 2019 Jan 15;20(2):81. doi: 10.1208/s12249-019-1297-z.

PMID:
30645705
4.

Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions.

Qureshi OS, Rowley TF, Junker F, Peters SJ, Crilly S, Compson J, Eddleston A, Björkelund H, Greenslade K, Parkinson M, Davies NL, Griffin R, Pither TL, Cain K, Christodoulou L, Staelens L, Ward E, Tibbitts J, Kiessling A, Smith B, Brennan FR, Malmqvist M, Fallah-Arani F, Humphreys DP.

Sci Rep. 2017 Dec 6;7(1):17049. doi: 10.1038/s41598-017-17255-8.

5.

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.

Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A.

Int J Nanomedicine. 2017 Oct 5;12:7291-7309. doi: 10.2147/IJN.S146315. eCollection 2017. Review.

6.

An immunofluorescence assay for extracellular matrix components highlights the role of epithelial cells in producing a stable, fibrillar extracellular matrix.

Qureshi OS, Bon H, Twomey B, Holdsworth G, Ford K, Bergin M, Huang L, Muzylak M, Healy LJ, Hurdowar V, Johnson TS.

Biol Open. 2017 Oct 15;6(10):1423-1433. doi: 10.1242/bio.025866.

7.

Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration.

Qureshi OS, Kim HS, Zeb A, Choi JS, Kim HS, Kwon JE, Kim MS, Kang JH, Ryou C, Park JS, Kim JK.

J Microencapsul. 2017 May;34(3):250-261. doi: 10.1080/02652048.2017.1337247. Epub 2017 Jun 15.

PMID:
28557649
8.

Enhanced anti-rheumatic activity of methotrexate-entrapped ultradeformable liposomal gel in adjuvant-induced arthritis rat model.

Zeb A, Qureshi OS, Yu CH, Akram M, Kim HS, Kim MS, Kang JH, Majid A, Chang SY, Bae ON, Kim JK.

Int J Pharm. 2017 Jun 15;525(1):92-100. doi: 10.1016/j.ijpharm.2017.04.032. Epub 2017 Apr 18.

PMID:
28428089
9.

High payload itraconazole-incorporated lipid nanoparticles with modulated release property for oral and parenteral administration.

Zeb A, Qureshi OS, Kim HS, Kim MS, Kang JH, Park JS, Kim JK.

J Pharm Pharmacol. 2017 Aug;69(8):955-966. doi: 10.1111/jphp.12727. Epub 2017 Apr 18.

PMID:
28421603
10.

Enhanced acute anti-inflammatory effects of CORM-2-loaded nanoparticles via sustained carbon monoxide delivery.

Qureshi OS, Zeb A, Akram M, Kim MS, Kang JH, Kim HS, Majid A, Han I, Chang SY, Bae ON, Kim JK.

Eur J Pharm Biopharm. 2016 Nov;108:187-195. doi: 10.1016/j.ejpb.2016.09.008. Epub 2016 Sep 12.

PMID:
27634645
11.

Improved skin permeation of methotrexate via nanosized ultradeformable liposomes.

Zeb A, Qureshi OS, Kim HS, Cha JH, Kim HS, Kim JK.

Int J Nanomedicine. 2016 Aug 8;11:3813-24. doi: 10.2147/IJN.S109565. eCollection 2016.

12.

Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function.

Jeffery LE, Qureshi OS, Gardner D, Hou TZ, Briggs Z, Soskic B, Baker J, Raza K, Sansom DM.

PLoS One. 2015 Jul 2;10(7):e0131539. doi: 10.1371/journal.pone.0131539. eCollection 2015.

13.

A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.

Hou TZ, Qureshi OS, Wang CJ, Baker J, Young SP, Walker LS, Sansom DM.

J Immunol. 2015 Mar 1;194(5):2148-59. doi: 10.4049/jimmunol.1401876. Epub 2015 Jan 28.

14.

A transendocytosis perspective on the CD28/CTLA-4 pathway.

Soskic B, Qureshi OS, Hou T, Sansom DM.

Adv Immunol. 2014;124:95-136. doi: 10.1016/B978-0-12-800147-9.00004-2. Review.

PMID:
25175774
15.

IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells.

Attridge K, Kenefeck R, Wardzinski L, Qureshi OS, Wang CJ, Manzotti C, Okkenhaug K, Walker LS.

J Immunol. 2014 Mar 1;192(5):2195-201. doi: 10.4049/jimmunol.1302082. Epub 2014 Jan 27.

16.

Comparison of the intracellular trafficking itinerary of ctla-4 orthologues.

Kaur S, Qureshi OS, Sansom DM.

PLoS One. 2013;8(4):e60903. doi: 10.1371/journal.pone.0060903. Epub 2013 Apr 2.

17.

Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses.

Jeffery LE, Wood AM, Qureshi OS, Hou TZ, Gardner D, Briggs Z, Kaur S, Raza K, Sansom DM.

J Immunol. 2012 Dec 1;189(11):5155-64. doi: 10.4049/jimmunol.1200786. Epub 2012 Oct 19.

18.

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells.

Wang CJ, Kenefeck R, Wardzinski L, Attridge K, Manzotti C, Schmidt EM, Qureshi OS, Sansom DM, Walker LS.

J Immunol. 2012 Aug 1;189(3):1118-22. doi: 10.4049/jimmunol.1200972. Epub 2012 Jun 29.

19.

Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation.

Qureshi OS, Kaur S, Hou TZ, Jeffery LE, Poulter NS, Briggs Z, Kenefeck R, Willox AK, Royle SJ, Rappoport JZ, Sansom DM.

J Biol Chem. 2012 Mar 16;287(12):9429-40. doi: 10.1074/jbc.M111.304329. Epub 2012 Jan 19.

20.

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM.

Science. 2011 Apr 29;332(6029):600-3. doi: 10.1126/science.1202947. Epub 2011 Apr 7.

21.

1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3.

Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker LS, Lammas DA, Raza K, Sansom DM.

J Immunol. 2009 Nov 1;183(9):5458-67. doi: 10.4049/jimmunol.0803217.

22.

Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.

Schmidt EM, Wang CJ, Ryan GA, Clough LE, Qureshi OS, Goodall M, Abbas AK, Sharpe AH, Sansom DM, Walker LS.

J Immunol. 2009 Jan 1;182(1):274-82.

23.

ATP-induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages.

Biswas D, Qureshi OS, Lee WY, Croudace JE, Mura M, Lammas DA.

BMC Immunol. 2008 Jul 15;9:35. doi: 10.1186/1471-2172-9-35.

24.

Assembly and trafficking of P2X purinergic receptors (Review).

Murrell-Lagnado RD, Qureshi OS.

Mol Membr Biol. 2008 May;25(4):321-31. doi: 10.1080/09687680802050385. Review.

PMID:
18446618
25.

Regulation of P2X4 receptors by lysosomal targeting, glycan protection and exocytosis.

Qureshi OS, Paramasivam A, Yu JC, Murrell-Lagnado RD.

J Cell Sci. 2007 Nov 1;120(Pt 21):3838-49. Epub 2007 Oct 16.

26.

Evidence for functional P2X4/P2X7 heteromeric receptors.

Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD.

Mol Pharmacol. 2007 Dec;72(6):1447-56. Epub 2007 Sep 4.

PMID:
17785580
27.

An uncharged region within the N terminus of the P2X6 receptor inhibits its assembly and exit from the endoplasmic reticulum.

Ormond SJ, Barrera NP, Qureshi OS, Henderson RM, Edwardson JM, Murrell-Lagnado RD.

Mol Pharmacol. 2006 May;69(5):1692-700. Epub 2006 Feb 1.

PMID:
16452399
28.

Non-canonical YXXGPhi endocytic motifs: recognition by AP2 and preferential utilization in P2X4 receptors.

Royle SJ, Qureshi OS, Bobanović LK, Evans PR, Owen DJ, Murrell-Lagnado RD.

J Cell Sci. 2005 Jul 15;118(Pt 14):3073-80. Epub 2005 Jun 28.

Supplemental Content

Loading ...
Support Center